SEINE BIO · PEPTIDE PROFILE
TB-500
Thymosin beta-4 fragment
ExperimentalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is TB-500?
The name can obscure molecular differences. The FDA-listed LKKTETQ fragment should not be treated as identical to full-length thymosin beta-4. Human safety evidence is insufficient. FDA safety context.
Explore the source
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of TB-500.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
TB-500 is a marketplace name associated with thymosin beta-4-related research, but product identity is not consistent across all discussions. FDA’s reference concerns the LKKTETQ fragment. Identifying whether a source studied a fragment or full-length thymosin beta-4 is the first step in understanding what its evidence can actually support.
Community Use
PeptideDosages and Peptidepedia discuss TB-500 in informal recovery settings. These publisher accounts explain the community interest. Their proposed protocols remain community claims rather than a verified human injury-care regimen, and the exact substance discussed needs to remain attached to each claim.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | Loading: 2–2.5 mg twice weekly; maintenance: 2 mg weekly or every 2 weeks | Phase dependent | Loading 4–6 weeks; maintenance 4–8 weeks Break: 4–8 weeks | Published informal biohacking claim PeptideWiki |
| Subcutaneous | Loading: 2–2.5 mg twice weekly; maintenance: 2–2.5 mg weekly | Phase dependent | Loading 4–6 weeks; maintenance duration not fixed in this summary Break: 4–8 weeks | Published informal biohacking claim Peptide Dosing Protocols |
Important context: The name can refer to a thymosin-beta-4 fragment or other material. Full-length thymosin-beta-4 studies do not validate a fragment sold as TB-500.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The chart attributes reported amounts and cycles to their named sources. An established human prescribing regimen for the marketed fragment is not supplied by the studies reviewed. Amounts used for another thymosin molecule, a different sequence or an animal model are not converted into personal treatment instructions.
Research Findings
A 1999 rat study investigated full-length thymosin beta-4 in a skin-wound model and examined wound closure, collagen and angiogenesis. It is useful primary research, but it is not a clinical trial of every product sold as TB-500. Molecular identity and the experimental model are essential to interpreting it.
U.S. Approval & Access
The sources reviewed do not establish an FDA-approved TB-500 injury medicine. FDA’s July 2026 advisory agenda includes TB-500-related substances in its compounding-list review. That process is distinct from marketing approval and a final compounding rule; the actual current pathway requires verification.
What It Does in the Body
Thymosin beta-4 research involves cell migration and tissue-repair biology. A shorter fragment can differ from the full protein in activity and exposure. Reliable human onset, peak clinical benefit and duration after stopping are not established for a community TB-500 regimen. A proposed loading phase does not supply those missing response data.
Benefits & Reported Experiences
The rat study found wound-model changes that support further investigation of its tested molecule. Those findings are not human tendon, muscle or ligament outcomes. A clinically meaningful recovery claim needs the correct substance, diagnosis and human endpoint rather than treating all thymosin-related research as evidence for one marketed vial.
Side Effects & Risks
FDA’s safety summary notes immune and peptide-impurity concerns for the fragment and a lack of identified human exposure data. That leaves important safety questions unresolved. A dependable personal side-effect probability cannot be calculated from informal use reports or the full-length rat study.
Delivery Options
Routes in experimental research and community reports differ. The route belongs to the actual molecule and formulation tested; topical wound-model evidence does not establish an injectable patient-care benefit. This article provides no injection technique, preparation steps or route-selection protocol.
Product Quality & Storage
Quality assessment starts with exact sequence and formulation, then considers identity, contaminants and accountability. A TB-500 label alone is not a pharmaceutical specification. No verified patient-use storage rule is supplied for community materials; any authorized program must define handling for its own product rather than importing another peptide’s shelf-life claim.
Combinations & Interactions
TB-500 and BPC-157 are frequently paired by informal publishers. That pairing should be evaluated as a distinct combination, with each material’s identity and evidence kept visible. No clinical combination schedule is established here. A blend also complicates understanding which component produced an effect or adverse reaction.
Talking With Your Provider
For persistent injury or pain, a qualified provider can identify the underlying problem and compare rehabilitation and other supported care. Thymosin research may be a useful discussion topic when its limits and identity are clear. The consultation should produce a care decision, without promising a fragment product, research enrollment or a recovery timetable.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →